Ultra-low-dose computed tomography (ULDCT) may have similar efficacy as low-dose CT (LDCT) for detecting a variety of pulmonary conditions in people with current or past smoking histories, but had poor detection of ground glass opacification lesions, according to a recent prospective study presented at the Radiological Society of North America (RSNA) conference.
In a recent poster presentation at the Radiological Society of North America (RSNA) conference, researchers shared preliminary findings from a prospective trial that compared the use of ultra-low-dose computed tomography (ULDCT) to low-dose CT (LDCT) in current smokers and those with a previous smoking history.
For the study, researchers examined the use of LDCT dosing (mean effective radiation dose of 1.40 mSv) versus ULDCT dosing (mean effective radiation dose of 0.39 mSv) in consecutive patients referred for lung cancer screening over a one-month period. The study cohort included current and previous smokers with a 20 pack-year history, according to the study. The researchers noted that 58 of the 265 enrolled patients had abnormal CT scans. The CT scans were reviewed by two senior thoracic radiologists.
The study authors found a 92 percent agreement between ULDCT and LDCT for emphysema and a 91 percent agreement for pulmonary nodules. Agreement for findings such as bronchial wall thickening, atelectasis and bronchiectasis ranged between 80 to 90 percent, according to the study.
However, the researchers noted that agreement between ULDCT and LDCT ranged between 60 to 80 percent for septal thickening, pleural effusion, and consolidation. They also noted poor agreement (37 percent) for ground glass opacification (GGO) lesions.
While the researchers noted the use of ULDCT could reduce effective radiation dosing to a third of that used for LDCT, they said the significant potential for missing other lung cancers such as lepidic adenocarcinoma outweigh the benefits of reduced radiation dosing.
“Despite the exciting agreement for some pulmonary findings, these results question whether using an ULDCT protocol for (lung cancer screening) would be adequate as many subsolid or GGO lesions could be missed,” wrote Matheus Zanon, MD, MSc, who is affiliated with the Department of Radiology at Pontificia Universidade Catolica do Rio Grande do Sul in Porto Alegre, Brazil, and colleagues.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which was unveiled at the American College of Cardiology (ACC) conference.
GE HealthCare Launches PET MPI Agent Flyrcado at ACC Conference
March 28th 2025The positron emission tomography myocardial perfusion imaging (PET MPI) agent, which offers a significantly higher half-life than other cardiac PET agents, was recently granted pass-through payment status by CMS that will go into effect on April 1, 2025.